1. Home
  2. VTR vs ONC Comparison

VTR vs ONC Comparison

Compare VTR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ventas Inc.

VTR

Ventas Inc.

N/A

Current Price

$85.78

Market Cap

41.1B

Sector

Real Estate

ML Signal

N/A

ONC

BeiGene Ltd. American Depositary Shares

N/A

Current Price

$299.34

Market Cap

33.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTR
ONC
Founded
1983
2010
Country
United States
Switzerland
Employees
N/A
12000
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.1B
33.5B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
VTR
ONC
Price
$85.78
$299.34
Analyst Decision
Buy
Strong Buy
Analyst Count
13
10
Target Price
$84.77
$386.70
AVG Volume (30 Days)
2.5M
224.8K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
2.42%
N/A
EPS Growth
184.21
N/A
EPS
0.54
N/A
Revenue
$5,833,980,000.00
N/A
Revenue This Year
$12.42
$759.19
Revenue Next Year
$8.32
$14.51
P/E Ratio
$159.15
$614.06
Revenue Growth
18.47
N/A
52 Week Low
$60.15
$196.53
52 Week High
$87.87
$385.22

Technical Indicators

Market Signals
Indicator
VTR
ONC
Relative Strength Index (RSI) 59.37 34.99
Support Level $66.18 $292.79
Resistance Level $87.56 $300.00
Average True Range (ATR) 1.35 9.26
MACD -0.36 -4.29
Stochastic Oscillator 44.83 12.16

Price Performance

Historical Comparison
VTR
ONC

About VTR Ventas Inc.

Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

About ONC BeiGene Ltd. American Depositary Shares

BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.

Share on Social Networks: